- An inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH) designed to improve the therapeutic profile of treprostinil by enhancing deep lung delivery and achieving higher dose levels than current inhaled therapies
- PAH is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death, with an estimated prevalence in the United States of approximately 30,000 patients
- Learn more about the pivotal Phase 3 trial, known as INSPIRE
- Results of studies with LIQ861 can be found on our ‘Publications’ page
Liquidia is a biopharmaceutical company focused on the development and commercialization of products that address unmet patient needs, with current focus directed towards the treatment of pulmonary arterial hypertension (PAH). Our current pipeline is focused on the development of product candidates using our PRINT® Technology platform, which includes LIQ861 for the treatment of pulmonary arterial hypertension.